Kamada Ltd. (KMDA) Expected to Post Quarterly Sales of $25.99 Million

Brokerages expect Kamada Ltd. (NASDAQ:KMDA) to post $25.99 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Kamada’s earnings. The highest sales estimate is $27.90 million and the lowest is $24.07 million. Kamada reported sales of $22.92 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 13.4%. The firm is scheduled to announce its next earnings results on Monday, November 12th.

On average, analysts expect that Kamada will report full year sales of $111.52 million for the current year, with estimates ranging from $105.00 million to $118.80 million. For the next year, analysts expect that the firm will report sales of $147.76 million, with estimates ranging from $128.20 million to $177.68 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Kamada.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. Kamada had a net margin of 11.79% and a return on equity of 14.43%. The business had revenue of $33.84 million for the quarter, compared to analysts’ expectations of $29.64 million.

Several research firms have recently commented on KMDA. ValuEngine upgraded shares of Kamada from a “strong sell” rating to a “sell” rating in a report on Monday, July 16th. Zacks Investment Research cut shares of Kamada from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. HC Wainwright set a $11.00 price objective on shares of Kamada and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, BidaskClub upgraded shares of Kamada from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $8.08.

Kamada stock opened at $5.93 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 3.95. Kamada has a 12 month low of $4.26 and a 12 month high of $6.45. The firm has a market cap of $249.63 million, a PE ratio of 32.94 and a beta of 1.20.

A number of large investors have recently modified their holdings of KMDA. Acadian Asset Management LLC lifted its position in Kamada by 157.8% during the 2nd quarter. Acadian Asset Management LLC now owns 292,795 shares of the biotechnology company’s stock worth $1,507,000 after acquiring an additional 179,237 shares during the last quarter. Renaissance Technologies LLC lifted its position in Kamada by 8.1% during the 2nd quarter. Renaissance Technologies LLC now owns 464,900 shares of the biotechnology company’s stock worth $2,417,000 after acquiring an additional 34,800 shares during the last quarter. Jane Street Group LLC acquired a new position in Kamada during the 2nd quarter worth $146,000. Macquarie Group Ltd. lifted its position in Kamada by 71.7% during the 2nd quarter. Macquarie Group Ltd. now owns 47,547 shares of the biotechnology company’s stock worth $247,000 after acquiring an additional 19,851 shares during the last quarter. Finally, ARK Investment Management LLC lifted its position in Kamada by 14.8% during the 2nd quarter. ARK Investment Management LLC now owns 119,537 shares of the biotechnology company’s stock worth $616,000 after acquiring an additional 15,440 shares during the last quarter. Hedge funds and other institutional investors own 11.24% of the company’s stock.

Kamada Company Profile

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).

Recommended Story: How Important is Technical Analysis of Stocks

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kamada (NASDAQ:KMDA)

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply